SLC5A2 and chronic kidney disease: In additional to the traditional renin-angiotensin-aldosterone system (RAAS) blockers, sodium-glucose cotransporter 2 (SGLT2) inhibitors are efficacious in providing renal protection for both DKD and non-diabetic chronic kidney disease (CKD) [7–9].